Resources

Helpful tools for you and your patients

At Mallinckrodt, we strive to provide healthcare professionals with the resources they need to educate themselves, their staff, and their patients on the proper use of Acthar and the many different disease states for which it is indicated. Review this section for helpful materials for your practice and patients. You’ll also find a simple way to request a visit from an Acthar Specialty Sales Consultant.

Videos

SC Injection Training Video

Step-by-step instructions on how to inject Acthar subcutaneously.

Step-by-step instructions on how to inject Acthar subcutaneously.1:22

IM Injection Training Video

Step-by-step instructions on how to inject Acthar intramuscularly.

Step-by-step instructions on how to inject Acthar subcutaneously.1:19

Mechanism of Action Video

This video explains how Acthar is thought to work.

Step-by-step instructions on how to inject Acthar subcutaneously.9:20

Resources for your practice

patient-brouchure

The Acthar Initiation Kit

Includes information and instruction on how to get a patient started on Acthar.

acthar-PI

Acthar Referral/Prescription Form

Download, complete, and fax the Referral/Prescription Form to order Acthar for your patients.

Resources for your patients

patient-brouchure

Exploring Treatment Options for Uveitis

Includes information on uveitis, inflammatory eye conditions, and treatment options.

acthar-PI

Your Guide to Acthar

Information for your patients on how Acthar is thought to work, how to take Acthar, and how to work with you and the Acthar Specialty Pharmacy to get the medication.

Injection_brochure

Injection Guide

More information for your patients about storing, preparing, and injecting Acthar.

journal_guide

Treatment Journal

A helpful tool for your patients to keep track of their Acthar treatment and jot down questions to ask their healthcare provider.

Specialty Sales Consultant

Request a visit from an Acthar Specialty Sales Consultant

If you would like to get more information about Acthar, you can request a visit from an Acthar Specialty Sales Consultant. Simply fill out the form below, and one will contact you. Please verify the information provided is correct in the e-mail generated and click send.

All fields are required except where noted.
This field is incomplete or invalid This field is incomplete or invalid This field is incomplete or invalid This field is incomplete or invalid This field is incomplete or invalid This field is incomplete or invalid This field is incomplete or invalid This field is incomplete or invalid This field is incomplete or invalid This field is incomplete or invalid
Please accept the terms
Please confirm

To report a side effect/adverse drug experience or quality complaint, please call Mallinckrodt Medical Information at 1-800-778-7898.

Acthar is indicated for severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: keratitis, iritis, iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, anterior segment inflammation.

Important Safety Information

SEE More

Contraindications

  • Acthar should never be administered intravenously
  • Administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of Acthar

Important Safety Information

CLOSE

Contraindications

  • Acthar should never be administered intravenously
  • Administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of Acthar
  • Acthar is contraindicated where congenital infections are suspected in infants
  • Acthar is contraindicated in patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction or sensitivity to proteins of porcine origins

Warning and Precautions

  • The adverse effects of Acthar are related primarily to its steroidogenic effects
  • Acthar may increase susceptibility to new infection or reactivation of latent infections
  • Suppression of the hypothalamic-pituitary-axis (HPA) may occur following prolonged therapy with the potential for adrenal insufficiency after withdrawal of the medication. Adrenal insufficiency may be minimized by tapering of the dose when discontinuing treatment. During recovery of the adrenal gland patients should be protected from the stress (e.g. trauma or surgery) by the use of corticosteroids. Monitor patients for effects of HPA suppression after stopping treatment
  • Cushing’s Syndrome may occur during therapy but generally resolves after therapy is stopped. Monitor patients for signs and symptoms
  • Acthar can cause elevation of blood pressure, salt and water retention, and hypokalemia. Blood pressure, sodium and potassium levels may need to be monitored
  • Acthar often acts by masking symptoms of other diseases/disorders. Monitor patients carefully during and for a period following discontinuation of therapy
  • Acthar can cause GI bleeding and gastric ulcer. There is also an increased risk for perforation in patients with certain gastrointestinal disorders. Monitor for signs of bleeding
  • Acthar may be associated with central nervous system effects ranging from euphoria, insomnia, irritability, mood swings, personality changes, and severe depression, and psychosis. Existing conditions may be aggravated
  • Patients with comorbid disease may have that disease worsened. Caution should be used when prescribing Acthar in patients with diabetes and myasthenia gravis
  • Prolonged use of Acthar may produce cataracts, glaucoma and secondary ocular infections. Monitor for signs and symptoms
  • Acthar is immunogenic and prolonged administration of Acthar may increase the risk of hypersensitivity reactions. Neutralizing antibodies with chronic administration may lead to loss of endogenous ACTH activity
  • There is an enhanced effect in patients with hypothyroidism and in those with cirrhosis of the liver
  • Long-term use may have negative effects on growth and physical development in children. Monitor pediatric patients
  • Decrease in bone density may occur. Bone density should be monitored for patients on long-term therapy
  • Pregnancy Class C: Acthar has been shown to have an embryocidal effect and should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus

Adverse Reactions

  • Common adverse reactions for Acthar are similar to those of corticosteroids and include fluid retention, alteration in glucose tolerance, elevation in blood pressure, behavioral and mood changes, increased appetite and weight gain
  • Specific adverse reactions reported in IS clinical trials in infants and children under 2 years of age included: infection, hypertension, irritability, Cushingoid symptoms, constipation, diarrhea, vomiting, pyrexia, weight gain, increased appetite, decreased appetite, nasal congestion, acne, rash, and cardiac hypertrophy. Convulsions were also reported, but these may actually be occurring because some IS patients progress to other forms of seizures and IS sometimes mask other seizures, which become visible once the clinical spasms from IS resolve

Other adverse events reported are included in the full Prescribing Information.

Please see full Prescribing Information.

References